Comparing antibody and small-molecule therapies for cancer
By K. Imai, A. Takaoka. Nature Reviews. Cancer, 2006
793 citations recorded by the source corpus.
The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.
Subfields: Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/222da645f4b7f2cdddc53d00a134828fd0dd6d88
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies (2010, background): “mAbs accomplish their effect through direct action on their target and/or indirectly by action mediated by the immune system: antibody-dependent cellular toxicity (ADCC) and/or cell-dependent cytotoxicity (CDC).([4]) It is estimated that about 150 mAbs are currently in clinical development,([5]) and”
- Therapeutic peptides: current applications and future directions (2022, background): “High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes.”
- Wnt/β-catenin signaling in cancers and targeted therapies (2021, background): “Therefore, in in vivo experiments with a complete immune system, mAbs may show better antitumor effects than in in vitro experiments.(274) In addition, mAbs can serve as the vehicle to achieve precision medicine, such as targeting radiogen to tumors.”
- Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “Advantages of immunostimulatory mAbs IgG mAbs are large, complex proteins that are resistant to degradation in serum and have molecular features that ensure they remain in the circulation for an extended perio”